Shingles, medically known as herpes zoster (HZ), is caused by the reactivation of the varicella-zoster virus—the same virus responsible for chickenpox. Once a person recovers from chickenpox, the virus remains dormant in nerve tissues. Years later, it can reactivate, leading to a painful rash and potential complications [1], [3]. A life-course immunization strategy helps improve societal well-being and is heavily recommended to mitigate these risks, particularly in older adults [1].
Global Perspectives on Shingles Vaccination
Vaccination is the most effective way to prevent shingles and its complications, such as post-herpetic neuralgia. However, global willingness to receive the herpes zoster vaccine varies significantly across different regions and countries [1]. Sociodemographic variables and individual perceptions heavily influence whether a person chooses to get vaccinated [1]. Healthcare initiatives continually aim to address these hesitations by providing clear, evidence-based education about vaccine safety and efficacy.
Vaccine Effectiveness in Vulnerable Populations
Recent studies have evaluated the performance of the recombinant zoster vaccine (RZV) in specific patient groups, such as adults diagnosed with multiple sclerosis (MS) [2]. A large-scale retrospective US claims-based study analyzed vaccinated and unvaccinated MS patients insured by Medicare or commercial health plans [2]. The findings help clinicians understand how well the recombinant zoster vaccine protects individuals who have underlying immune-mediated conditions [2]. Ensuring high-risk populations receive proper protection remains a cornerstone of preventative medicine.
Clinical Manifestations and Varied Presentations
While shingles typically presents as a localized, blistering rash along a specific dermatome, unexpected presentations can occasionally occur. For instance, medical literature has documented cases where herpes zoster ophthalmicus—involving the ophthalmic division of the trigeminal nerve—manifested shortly after unrelated medical procedures like dental root canal therapy [3]. Patients in such cases may experience severe migraine-like neuropathic pain, periorbital swelling, and skin eruptions [3]. Recognizing these atypical presentations promptly is critical to prevent severe, vision-threatening complications [3].
Antiviral Therapy and Management Strategies
When shingles does develop, early recognition and prompt initiation of systemic antiviral therapy are essential for reducing the severity and duration of the illness [3]. In clinical settings, antiviral medications help accelerate the healing of lesions and lower the risk of long-term nerve pain. For patients undergoing specific immunosuppressive treatments or managing malignant conditions, risk-adapted antiviral prophylaxis is frequently utilized to suppress viral reactivation and protect overall health [8].
Sources
- [1] Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis
- [2] Effectiveness of the recombinant zoster vaccine in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States
- [3] Herpes Zoster Ophthalmicus Following Endodontic Treatment: A Case Report
- [8] Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)